Exchange: NYSE·Updated 11:00 AM EDT
News
all
press releases
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Zacks
More News
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Zacks
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
Zacks
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
Zacks
GSK Makes Bullish Cross Above Critical Moving Average
In trading on Wednesday, shares of Gsk plc American Depositary Shares (each Represent (Symbol: GSK) crossed above their 200 day moving average of $52.03, changing hands as high as $52.73 per share. Gsk plc American Depositary Shares (each Represent shares are currently trading...
Nasdaq News: Markets
Vaccine-Maker Claims Splitting MMR Shot Could Take Up To 10 Years
Vaccine-Maker Claims Splitting MMR Shot Could Take Up To 10 Years Authored by Zachary Stieber via The Epoch Times, Splitting the measles, mumps, rubella (MMR) vaccine into separate shots could take up to a decade, according to one of the two companies that produce the vaccine for the...
Zero Hedge
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Zacks
PFE, MRK, SNY, MRNA In Focus As Trump Reportedly Eyes Executive Order On Vaccines And Autism
The order’s contents remain unclear, and timing could shift, Bloomberg reported, citing people familiar with the matter.
Stocktwits
Moderna's mRNA Flu Vaccine Approved By FDA
Moderna's mRNA Flu Vaccine Approved By FDA Authored by Rachel Roberts via The Epoch Times, The U.S. Food and Drug Administration has approved Moderna's flu shot for over-50s, marking the first time the agency has licensed a messenger ribonucleic acid (mRNA) vaccine for seasonal...
Zero Hedge
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.
Zacks

Advertisement|Remove ads.